News - Circle Pharma

Background Publications on Macrocycles

Our Science

The Promise of Macrocycles

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut. labore et dolore magnam aliquam quaerat voluptatem.

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer

June 16, 2025

A Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class Cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle

June 2, 2025

Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

May 27, 2025

CID-078, an orally bioavailable Cyclin A/B-RxL inhibitor elicits anti-tumor activity in neuroblastoma models

May 27, 2025

Circle Pharma to present Trials in Progress poster on CID-078, a first-in-class cyclin A/B inhibitor, at the ASCO 2025 Annual Meeting

May 12, 2025

Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/CHK1 DNA repair pathway

April 29, 2025

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors

April 22, 2025

Circle Pharma to Present at the Upcoming Investor Conferences

March 31, 2025

CID-078, a first-in-class oral Cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models

December 9, 2024